September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Clincal trial: subretinal transplantation of CTS hESC derived RPE in the treatment of wet Age-related Macular Degeneration (wAMD)
Author Affiliations & Notes
  • Zheng Qin Yin
    Ophthalmology, Southwest Hospital, Third Military Medical University, Chongqing, China
  • Yong Liu
    Ophthalmology, Southwest Hospital, Third Military Medical University, Chongqing, China
  • Shiying Li
    Ophthalmology, Southwest Hospital, Third Military Medical University, Chongqing, China
  • Hai Wei Xu
    Ophthalmology, Southwest Hospital, Third Military Medical University, Chongqing, China
  • Yi Wang
    Ophthalmology, Southwest Hospital, Third Military Medical University, Chongqing, China
  • Chen Qian
    Southwest Hospital,Third Military Medical University, Chongqing, China
  • Qi Zhou
    Institute of zoology,Chinese Acadamy of Sciences, Beijing, China
  • Footnotes
    Commercial Relationships   Zheng Qin Yin, None; Yong Liu, None; Shiying Li, None; Hai Wei Xu, None; Yi Wang, None; Chen Qian, None; Qi Zhou, None
  • Footnotes
    Support  National Basic Research Program of China No.2013CB967002
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3742. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Zheng Qin Yin, Yong Liu, Shiying Li, Hai Wei Xu, Yi Wang, Chen Qian, Qi Zhou; Clincal trial: subretinal transplantation of CTS hESC derived RPE in the treatment of wet Age-related Macular Degeneration (wAMD). Invest. Ophthalmol. Vis. Sci. 2016;57(12):3742.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the safety and efficacy of Retinal pigment epithelium (RPE) transplantation for retinal degenerative diseases affecting the RPE-photoreceptor complex, clinically to treat the AMD and Stargardt’s disease.

Methods : The xeno-free clinical-grade human embryonic stem cell line (CTS hESC) was induced to RPE cells by spontaneous differentiation method. A serious of safety assessments were finished for potential bacteria, mycoplasma, murine viruses according to standard protocols. The characteristics of this CTS hESC derived RPE-specific attributes including purity, differentiation and phagocytosis by quantitative PCR, FACS and immunohistochemistry staining. The purified CTS hESC derived RPE at passage 3 were used for clinical purpose. After registered with ClinicalTrials.gov (ChiCTR-OCB-15006423), we performed clinical study of subretinal transplantation of CTS hESC derived RPE in treatment of wet Age-related Macular Degeneration (wAMD).

Results : The first three patients underwent vitrectomy and removal of choroidal neovascularization (CNV) membrane successfully. During the three months follow-up till now, there were no rejection showed in the clinical tests, interestingly all three patients had improved their vision 7, 15 to 41 letters respectively in ETDRS visual acuity test and the patients’ previous feeling of central vision blurry due to CNV disappeared.

Conclusions : As we know this is the first study of subretinal transplantation of hESC derived RPE in the treatment of wet Age-related Macular Degeneration, which opened a new approach for the treatment of retinal degeneration diseases by the human embryonicstem cells in clinics.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×